Search

Your search keyword '"Martins, Karen"' showing total 327 results
Start Over Author "Martins, Karen" Publication Year Range Last 50 years
327 results on '"Martins, Karen"'

1. Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Author

Carpp, Lindsay N., Hyrien, Ollivier, Fong, Youyi, Benkeser, David, Roels, Sanne, Stieh, Daniel J., Van Dromme, Ilse, Van Roey, Griet A., Kenny, Avi, Huang, Ying, Carone, Marco, McDermott, Adrian B., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob C., Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, O’Connell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos J., Luedtke, Alex, Lu, Yiwen, Yu, Chenchen, Juraska, Michal, Hejazi, Nima S., Wolfe, Daniel N., Sadoff, Jerald, Gray, Glenda E., Grinsztejn, Beatriz, Goepfert, Paul A., Bekker, Linda-Gail, Gaur, Aditya H., Veloso, Valdilea G., Randhawa, April K., Andrasik, Michele P., Hendriks, Jenny, Truyers, Carla, Vandebosch, An, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.

Published
2024
Full Text
View/download PDF

2. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Author

Zhang, Bo, Fong, Youyi, Fintzi, Jonathan, Chu, Eric, Janes, Holly E., Kenny, Avi, Carone, Marco, Benkeser, David, van der Laan, Lars W. P., Deng, Weiping, Zhou, Honghong, Wang, Xiaowei, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, Chen, Haiyan, Reeder, Isabel, Carpp, Lindsay N., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Huynh, Chuong, Fichtenbaum, Carl J., Kalams, Spyros, Gay, Cynthia L., Andrasik, Michele P., Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Priddy, Frances, Das, Rituparna, Girard, Bethany, El Sahly, Hana M., Baden, Lindsey R., Jones, Thomas, Donis, Ruben O., Koup, Richard A., Gilbert, Peter B., and Follmann, Dean

Published
2024
Full Text
View/download PDF

4. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Author

Huang, Ying, Hejazi, Nima S, Blette, Bryan, Carpp, Lindsay N, Benkeser, David, Montefiori, David C, McDermott, Adrian B, Fong, Youyi, Janes, Holly E, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R, Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C, O’Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Kenny, Avi, Carone, Marco, Huynh, Chuong, Miller, Jacqueline, Sahly, Hana M El, Baden, Lindsey R, Jackson, Lisa A, Campbell, Thomas B, Clark, Jesse, Andrasik, Michele P, Kublin, James G, Corey, Lawrence, Neuzil, Kathleen M, Pajon, Rolando, Follmann, Dean, Donis, Ruben O, Koup, Richard A, Gilbert, Peter B, Assays, on behalf of the Immune, Moderna, Inc, Efficacy, Coronavirus Vaccine Prevention Network Coronavirus, and Teams, Government CoVPN Biostatistics

Subjects
Microbiology, Biological Sciences, Infectious Diseases, Biotechnology, Vaccine Related, Emerging Infectious Diseases, Immunization, Coronaviruses, Good Health and Well Being, Humans, 2019-nCoV Vaccine mRNA-1273, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Immunoglobulin G, Vaccine Efficacy, binding antibody assay, immune correlates of protection, modified treatment policy, neutralizing antibody assay, principal stratification, principal surrogate, SARS-CoV-2, stochastic intervention, stochastic interventional vaccine efficacy
Abstract

The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs.

Published
2023

5. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.

Author

Fong, Youyi, McDermott, Adrian, Benkeser, David, Roels, Sanne, Stieh, Daniel, Vandebosch, An, Le Gars, Mathieu, Van Roey, Griet, Houchens, Christopher, Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob, Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, OConnell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos, Luedtke, Alex, Hyrien, Ollivier, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars, Hejazi, Nima, Kenny, Avi, Carone, Marco, Wolfe, Daniel, Sadoff, Jerald, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul, Little, Susan, Paiva de Sousa, Leonardo, Maboa, Rebone, Randhawa, April, Andrasik, Michele, Hendriks, Jenny, Truyers, Carla, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James, Corey, Lawrence, Neuzil, Kathleen, Carpp, Lindsay, Follmann, Dean, Gilbert, Peter, Koup, Richard, and Donis, Ruben

Subjects
Humans, Ad26COVS1, COVID-19, ChAdOx1 nCoV-19, 2019-nCoV Vaccine mRNA-1273, Vaccine Efficacy, Antibodies, Neutralizing
Abstract

Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4 weeks post vaccination as correlates of risk of moderate to severe-critical COVID-19 through 83 d post vaccination in the phase 3, double-blind placebo-controlled phase of ENSEMBLE, an international randomized efficacy trial of a single dose of Ad26.COV2.S. We also evaluated correlates of protection in the trial cohort. Of the three antibody immune markers we measured, we found most support for 50% inhibitory dilution (ID50) neutralizing antibody titre as a correlate of risk and of protection. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; P = 0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43%, 72%) at non-quantifiable ID50 (

Published
2022

6. Regulatory T-cells and GARP expression are decreased in exercise-associated chikungunya viral arthritis flares.

Author

Dobbs, John E, Tritsch, Sarah R, Encinales, Liliana, Cadena, Andres, Suchowiecki, Karol, Simon, Gary, Mores, Christopher, Insignares, Silvana, Orozco, Vierys Patricia Villamil, Ospino, Mirna, Echavez, Lil Avendano, Gomez, Carlos Andres Herrera, Crespo, Yerlenis Galvis, Amdur, Richard, Jimenez, Alberto David Cabana, Hernandez, Carlos Alberto Perez, Zapata, Jennifer Carolina Martinez, Hernandez, Alfonso Sucerquia, Silvera, Paula Bruges, Rosales, Wendy, Mendoza, Evelyn, Osorio-Llanes, Estefanie, Castellar, Jairo, Jimenez, Dennys, Cooper, Dan M, Firestein, Gary S, Martins, Karen, and Chang, Aileen Y

Subjects
Leukocytes, Mononuclear, Humans, Chikungunya virus, Arthritis, Immunoglobulin G, T-Lymphocytes, Regulatory, Chikungunya Fever, Symptom Flare Up, GARP, chikungunya, chikungunya arthritis, clinical trials, exercise, immunology & infectious diseases, inflammation, viral arthritis, Prevention, Clinical Research, Vaccine Related, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Good Health and Well Being, Immunology, Medical Microbiology
Abstract

ObjectiveChikungunya virus (CHIKV) causes persistent arthritis, and our prior study showed that approximately one third of CHIKV arthritis patients had exacerbated arthritis associated with exercise. The underlying mechanism of exercise-associated chikungunya arthritis flare (EACAF) is unknown, and this analysis aimed to examine the regulatory T-cell immune response related to CHIKV arthritis flares.MethodsIn our study, 124 Colombian patients with a history of CHIKV infection four years prior were enrolled and 113 cases with serologically confirmed CHIKV IgG were used in this analysis. Patient information was gathered via questionnaires, and blood samples were taken to identify total live peripheral blood mononuclear cells, CD4+ cells, T regulatory cells, and their immune markers. We compared outcomes in CHIKV patients with (n = 38) vs. without (n = 75) EACAF using t-tests to assess means and the Fisher's exact test, chi-squared to evaluate categorical variables, and Kruskal-Wallis tests in the setting of skewed distributions (SAS 9.3).Results33.6% of CHIKV cases reported worsening arthritis with exercise. EACAF patients reported higher global assessments of arthritis disease ranging from 0-100 (71.2 ± 19.7 vs. 59.9 ± 28.0, p=0.03). EACAF patients had lower ratios of T regulatory (Treg)/CD4+ T-cells (1.95 ± 0.73 vs. 2.4 ± 1.29, p = 0.04) and lower percentage of GARP (glycoprotein-A repetitions predominant) expression per Treg (0.13 ± 0.0.33 vs. 0.16 ± 0.24 p= 0.020).ConclusionThese findings suggest relative decreases in GARP expression may indicate a decreased level of immune suppression. Treg populations in patients with CHIKV arthritis may contribute to arthritis flares during exercise, though current research is conflicting.

Published
2022

10. Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Author

Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.

Published
2023
Full Text
View/download PDF

11. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Author

Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.

Published
2023
Full Text
View/download PDF

12. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Author

Benkeser, David, Fong, Youyi, Janes, Holly E., Kelly, Elizabeth J., Hirsch, Ian, Sproule, Stephanie, Stanley, Ann Marie, Maaske, Jill, Villafana, Tonya, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Ayala, Victor, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Carpp, Lindsay N., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Isaacs, Margaret Brewinski, Makhene, Mamodikoe, Tong, Tina, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Hoffman, Corey, Falsey, Ann R., Sobieszczyk, Magdalena, Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.

Published
2023
Full Text
View/download PDF

15. The Cytokine Profile in Acute Chikungunya Infection is Predictive of Chronic Arthritis 20 Months Post Infection.

Author

Chang, Aileen Y, Tritsch, Sarah, Reid, St Patrick, Martins, Karen, Encinales, Liliana, Pacheco, Nelly, Amdur, Richard L, Porras-Ramirez, Alexandra, Rico-Mendoza, Alejandro, Li, Guangzhao, Peng, Jin, Firestein, Gary S, Simon, Gary L, and Bethony, Jeff M

Subjects
alphavirus, arthritis, chikungunya, cytokine
Abstract

The cytokine profile during acute chikungunya infection that predicts future chronic arthritis has not yet been investigated. We conducted a nested case-control study comparing serum cytokine concentrations during acute chikungunya infection in cases (n = 121) that reported the presence of chronic joint pain versus age- and gender-matched controls (n = 121) who reported recovery at 20 months post infection. We observed that a robust cytokine response during acute infection was correlated with a decreased incidence of chronic joint pain and that low TNFα, IL-13, IL-2, and IL-4 during acute infection was predictive of chronic joint pain. These data suggest that a robust cytokine response is necessary for viral clearance and cytokines that are related to immune tolerance during acute infection may be protective for chronic arthritis pathogenesis.

Published
2018

16. Frequency of Chronic Joint Pain Following Chikungunya Virus Infection

Author

Chang, Aileen Y, Encinales, Liliana, Porras, Alexandra, Pacheco, Nelly, Reid, St Patrick, Martins, Karen AO, Pacheco, Shamila, Bravo, Eyda, Navarno, Marianda, Rico Mendoza, Alejandro, Amdur, Richard, Kamalapathy, Priyanka, Firestein, Gary S, Bethony, Jeffrey M, and Simon, Gary L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Pain Research, Prevention, Chronic Pain, Arthritis, Clinical Research, Musculoskeletal, Infection, Good Health and Well Being, Adult, Arthralgia, Arthritis, Infectious, Chikungunya Fever, Chikungunya virus, Colombia, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo estimate the frequency of chronic joint pain after infection with chikungunya virus in a Latin American cohort.MethodsA cross-sectional follow-up of a prospective cohort of 500 patients from the Atlántico Department, Colombia who were clinically diagnosed as having chikungunya virus during the 2014-2015 epidemic was conducted. Baseline symptoms and follow-up symptoms at 20 months were evaluated in serologically confirmed cases.ResultsAmong the 500 patients enrolled, 485 had serologically confirmed chikungunya virus and reported joint pain status. Patients were predominantly adults (mean ± SD age 49 ± 16 years) and female, had an education level of high school or less, and were of Mestizo ethnicity. The most commonly affected joints were the small joints, including the wrists, ankles, and fingers. The initial virus symptoms lasted a median of 4 days (interquartile range [IQR] 3-8 days). Sixteen percent of the participants reported missing school or work (median 4 days [IQR 2-7 days]). After 20 months, one-fourth of the participants had persistent joint pain. A multivariable analysis indicated that significant predictors of persistent joint pain included college graduate status, initial symptoms of headache or knee pain, missed work, normal activities affected, ≥4 days of initial symptoms, and ≥4 weeks of initial joint pain.ConclusionThis is the first report to describe the frequency of chikungunya virus-related arthritis in the Americas after a 20-month follow-up. The high frequency of chronic disease highlights the need for the development of prevention and treatment methods.

Published
2018

17. Chikungunya Arthritis Mechanisms in the Americas

Author

Chang, Aileen Y, Martins, Karen AO, Encinales, Liliana, Reid, St Patrick, Acuña, Marlon, Encinales, Carlos, Matranga, Christian B, Pacheco, Nelly, Cure, Carlos, Shukla, Bhavarth, Ruiz Arteta, Teofilo, Amdur, Richard, Cazares, Lisa H, Gregory, Melissa, Ward, Michael D, Porras, Alexandra, Rico Mendoza, Alejandro, Dong, Lian, Kenny, Tara, Brueggemann, Ernie, Downey, Lydia G, Kamalapathy, Priyanka, Lichtenberger, Paola, Falls, Orlando, Simon, Gary L, Bethony, Jeffrey M, and Firestein, Gary S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Arthritis, Vector-Borne Diseases, Rare Diseases, Infectious Diseases, Emerging Infectious Diseases, Genetics, 2.1 Biological and endogenous factors, Aetiology, Infection, Inflammatory and immune system, Good Health and Well Being, Arthritis, Infectious, Chikungunya Fever, Chikungunya virus, Cross-Sectional Studies, Female, Humans, Male, Synovial Fluid, Time Factors, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo determine if chikungunya virus persists in synovial fluid after infection, potentially acting as a causative mechanism of persistent arthritis.MethodsWe conducted a cross-sectional study of 38 Colombian participants with clinical chikungunya virus infection during the 2014-2015 epidemic who reported chronic arthritis and 10 location-matched controls without chikungunya virus or arthritis. Prior chikungunya virus infection status was serologically confirmed, and the presence of synovial fluid chikungunya virus, viral RNA, and viral proteins was determined by viral culture, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and mass spectrometry, respectively. Biomarkers were assessed by multiplex analysis.ResultsPatients with serologically confirmed chikungunya arthritis (33 of 38 [87%]) were predominantly female (82%) and African Colombian (55%) or white Colombian (33%), with moderate disease activity (mean ± SD Disease Activity Score in 28 joints 4.52 ± 0.77) a median of 22 months after infection (interquartile range 21-23 months). Initial symptoms of chikungunya virus infection included joint pain (97%), swelling (97%), stiffness (91%), and fever (91%). The most commonly affected joints were the knees (87%), elbows (76%), wrists (75%), ankles (56%), fingers (56%), and toes (56%). Synovial fluid samples from all patients with chikungunya arthritis were negative for chikungunya virus on qRT-PCR, showed no viral proteins on mass spectrometry, and cultures were negative. Case and control plasma cytokine and chemokine concentrations did not differ significantly.ConclusionThis is one of the largest observational studies involving analysis of the synovial fluid of chikungunya arthritis patients. Synovial fluid analysis revealed no detectable chikungunya virus. This finding suggests that chikungunya virus may cause arthritis through induction of potential host autoimmunity, suggesting a role for immunomodulating agents in the treatment of chikungunya arthritis, or that low-level viral persistence exists in synovial tissue only and is undetectable in synovial fluid.

Published
2018

20. Poststroke Care Pathways and Spasticity Treatment: A Retrospective Study in Alberta

Author

Satkunam, Lalith, Dukelow, Sean P., Yu, Jaime, McNeil, Stephen, Luu, Huong, Martins, Karen J.B., Vu, Khanh, Nguyen, Phuong Uyen, Richer, Lawrence, Williamson, Tyler, and Klarenbach, Scott W.

Abstract

ABSTRACTBackground:Limited evidence exists regarding care pathways for stroke survivors who do and do not receive poststroke spasticity (PSS) treatment.Methods:Administrative data was used to identify adults who experienced a stroke and sought acute care between 2012 and 2017 in Alberta, Canada. Pathways of stroke care within the health care system were determined among those who initiated PSS treatment (PSS treatment group: outpatient pharmacy dispensation of an anti-spastic medication, focal chemo-denervation injection, or a spasticity tertiary clinic visit) and those who did not (non-PSS treatment group). Time from the stroke event until spasticity treatment initiation, and setting where treatment was initiated were reported. Descriptive statistics were performed.Results:Health care settings within the pathways of stroke care that the PSS (n= 1,079) and non-PSS (n= 22,922) treatment groups encountered were the emergency department (86 and 84%), acute inpatient care (80 and 69%), inpatient rehabilitation (40 and 12%), and long-term care (19 and 13%), respectively. PSS treatment was initiated a median of 291 (interquartile range 625) days after the stroke event, and most often in the community when patients were residing at home (45%), followed by “other” settings (22%), inpatient rehabilitation (18%), long-term care (11%), and acute inpatient care (4%).Conclusions:To our knowledge, this is the first population based cohort study describing pathways of care among adults with stroke who subsequently did or did not initiate spasticity treatment. Areas for improvement in care may include strategies for earlier identification and treatment of PSS.

Published
2025
Full Text
View/download PDF

21. South American Hemorrhagic Fevers: A summary for clinicians

Author

Beitscher, Adam, Bhadelia, Nahid, Cieslak, Theodore J., Davey, Richard T., Dierberg, Kerry, Evans, Jared D., Frank, Maria G., Grein, Jonathan, Kortepeter, Mark G., Kraft, Colleen S., Kratochvil, Chris J., Martins, Karen, McLellan, Susan, Mehta, Aneesh K., Raabe, Vanessa, Risi, George, Sauer, Lauren, Shenoy, Erica S., Uyeki, Tim, and Webb, Camille M.

Published
2021
Full Text
View/download PDF

22. Recent successes in therapeutics for Ebola virus disease: no time for complacency

Author

Iversen, Patrick L, Kane, Christopher D, Zeng, Xiankun, Panchal, Rekha G, Warren, Travis K, Radoshitzky, Sheli R, Kuhn, Jens H, Mudhasani, Rajini R, Cooper, Christopher L, Shurtleff, Amy C, Nasar, Farooq, Sunay, Melek ME, Duplantier, Allen J, Eaton, Brett P, Zumbrun, Elizabeth E, Bixler, Sandra L, Martin, Shannon, Meinig, J Matthew, Chiang, Chih-Yuan, Sanchez-Lockhart, Mariano, Palacios, Gustavo F, Kugelman, Jeffrey R, Martins, Karen A, Pitt, Margaret L, Crozier, Ian, and Saunders, David L

Published
2020
Full Text
View/download PDF

24. Cytokine and T cell responses in post-chikungunya viral arthritis: A cross-sectional study

Author

Chang, Aileen Y., primary, Tritsch, Sarah R., additional, Herrera Gomez, Carlos Andres, additional, Encinales, Liliana, additional, Cadena Bonfanti, Andres, additional, Rosales, Wendy, additional, Mendoza-Torres, Evelyn, additional, Simmens, Samuel, additional, Amdur, Richard L., additional, Mores, Christopher N., additional, Fierbaugh, Paige, additional, Perez Hernandez, Carlos Alberto, additional, Avendaño, Geraldine, additional, Silvera, Paula Bruges, additional, Crespo, Yerlenis Galvis, additional, Jimenez, Alberto David Cabana, additional, Martinez Zapata, Jennifer Carolina, additional, Jimenez, Dennys, additional, Osorio-Llanes, Estefanie, additional, Castellar-Lopez, Jairo, additional, Suchowiecki, Karol, additional, Martins, Karen, additional, Gregory, Melissa, additional, Zuluaga, Ivan, additional, Proctor, Abigale, additional, Hernández, Alfonso Sucerquia, additional, Sierra-Carrero, Leandro, additional, Colpas, Maria Villanueva, additional, Hernandez, Juan Carlos Perez, additional, Quast, Andres Alberto Figueroa, additional, De Barros, Joaquin Andres Calderon, additional, Mejía, José Forero, additional, Ruiz, Johan Penagos, additional, Boyle, David, additional, Firestein, Gary S., additional, and Simon, Gary L., additional

Published
2024
Full Text
View/download PDF

27. OS EFEITOS NEGATIVOS DO USO EXCESSIVO DE DISPOSITIVOS DE MÍDIAS ELETRÔNICA E SOCIAL NA SAÚDE MENTAL

Author

Giordani, Jéssica dos Santos, primary, Moreira, Beatriz Silva Argôlo, additional, Silva, Francielli Cristina da, additional, Martins, Karen Gibson Terra Ferreira, additional, Mota, Luiza Pinheiro, additional, Villela, Marcela C, additional, SUGUINOSHITA, POLLYANA YURI SALLES, additional, Oliveira, Anna Mariah Ribeiro, additional, Sá, Larissa Ellen Meneses de, additional, Nascimento, Bruna Katharine Cavalcante, additional, and Souza, Francine Saccani de Oliveira, additional

Published
2021
Full Text
View/download PDF

30. ANALYSIS OF APPROACHES, COMPLICATIONS AND LONG-TERM RESULTS OF BARIATRIC SURGERY: AN INTEGRATIVE REVIEW

Author

Andrade, Ísis Nader Araújo, primary, Andrade, Arthur Nader Araújo, additional, Andrade, Lucas Araújo, additional, Paula, Thalena Rocha de, additional, Miranda, Bruno Sol, additional, Souza, Bruno de Oliveira Passos, additional, Souza, Heloisa Martins Chaves de, additional, Coutinho, Athos Nogueira de Paula, additional, Moreira, Francisco Pedroni, additional, Bastianello, Matheus Alves, additional, Silva, Marco Aurélio Lacerda, additional, and Martins, Karen de Souza Salles, additional

Published
2023
Full Text
View/download PDF

31. Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada

Author

Richer, Lawrence, primary, Luu, Huong, additional, Martins, Karen J. B., additional, Vu, Khanh, additional, Guigue, Alexis, additional, Wong, Kai On, additional, Nguyen, Phuong Uyen, additional, Rajapakse, Thilinie, additional, Williamson, Tyler, additional, and Klarenbach, Scott W., additional

Published
2023
Full Text
View/download PDF

32. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting

Author

Sprecher, Armand, primary, Cross, Robert, additional, Marzi, Andrea, additional, Martins, Karen A, additional, Wolfe, Daniel, additional, Montgomery, Joel M, additional, Spiropoulou, Christina F, additional, Cihlar, Tomas, additional, Ahuka-Mundeke, Steve, additional, Nyhuis, Tara, additional, Teicher, Carrie, additional, Crozier, Ian, additional, Strong, Jim, additional, Kobinger, Gary, additional, Woolsey, Courtney, additional, Geisbert, Thomas W, additional, Feldmann, Heinz, additional, and Muyembe, Jean-Jacques, additional

Published
2023
Full Text
View/download PDF

37. FATORES ASSOCIADOS AOS RISCOS DE QUEDAS EM IDOSOS

Author

Durães, Renata Ribeiro, primary, Dos Santos, Joyce Lorena Pereira, additional, Martins, Karen Samille de Araujo, additional, Pestana, Priscylla Ruany Mendes, additional, Lopes, João Vitor Nunes, additional, Fagundes, Paulo Tadeu Morais, additional, and Fonseca, Bruno Henrique de Souza, additional

Published
2023
Full Text
View/download PDF

39. Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome

Author

Chang, Aileen Y., Lynch, Rebecca, Martins, Karen, Encinales, Liliana, Cadena Bonfanti, Andrés Á., Pacheco, Nelly, Reid, St. Patrick, Lara Sarabia, Osvaldo E., González Torres, Henry J., Mejia Castillo, Stella, Barrios Taborda, Onaldo, Alarcon Gomez, Magda, Guerra Duran, Brenda, Martinez Giraldo, Victor, Benitez Ospino, Angélica, Porras, Alexandra, Mendoza, Alejandro R., Mantus, Grace, Li, Guangzhao, Peng, Jin, Kamalapathy, Priyanka, Avendaño Echavez, Lil G., Dowd, Kimberly A., Rengifo-Pardo, Monica, Barraza, Pedro Pablo, Jiménez Hernàndez, Dennys, González Coba, Andrés, De La Hoz Mendoza, Katya, Bethony, Jeffrey M., and Simon, Gary L.

Published
2018
Full Text
View/download PDF

40. Chemical control of California arrowhead (Sagittaria montevidensis) resistant to acetolactate synthase and photosystem II inhibiting herbicides in irrigated rice/Manejo quimico de sagitaria (Sagittaria montevidensis) resistente aos herbicidas inibidores de Acetolactato Sintase e Fotossistema II aplicados em arroz irrigado

Author

Moura, Diogo da Silva, Noldin, Jose Alberto, Galon, Leandro, Helgueira, Diogo Balbe, Martins, Karen Piraine, and Cassol, Luciano Luis

Published
2016
Full Text
View/download PDF

41. Regulatory T-cells and GARP expression are decreased in exercise-associated chikungunya viral arthritis flares

Author

Dobbs, John E., primary, Tritsch, Sarah R., additional, Encinales, Liliana, additional, Cadena, Andres, additional, Suchowiecki, Karol, additional, Simon, Gary, additional, Mores, Christopher, additional, Insignares, Silvana, additional, Orozco, Vierys Patricia Villamil, additional, Ospino, Mirna, additional, Echavez, Lil Avendano, additional, Gomez, Carlos Andres Herrera, additional, Crespo, Yerlenis Galvis, additional, Amdur, Richard, additional, Jimenez, Alberto David Cabana, additional, Hernandez, Carlos Alberto Perez, additional, Zapata, Jennifer Carolina Martinez, additional, Hernandez, Alfonso Sucerquia, additional, Silvera, Paula Bruges, additional, Rosales, Wendy, additional, Mendoza, Evelyn, additional, Osorio-Llanes, Estefanie, additional, Castellar, Jairo, additional, Jimenez, Dennys, additional, Cooper, Dan M., additional, Firestein, Gary S., additional, Martins, Karen, additional, and Chang, Aileen Y., additional

Published
2022
Full Text
View/download PDF

48. Additional file 2 of Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study

Author

Wong, Kai On, Klarenbach, Scott W., Martins, Karen J. B., Chue, Pierre, Dursun, Serdar M., Snaterse, Mark, Guigue, Alexis, So, Helen, Luu, Huong, Vu, Khanh, and Richer, Lawrence

Abstract

Additional file 2. Identification of oral and long-acting injectable antipsychotics based on anatomical therapeutic chemical classification and/or drug identification number.

Published
2022
Full Text
View/download PDF

50. Additional file 5 of Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study

Author

Wong, Kai On, Klarenbach, Scott W., Martins, Karen J. B., Chue, Pierre, Dursun, Serdar M., Snaterse, Mark, Guigue, Alexis, So, Helen, Luu, Huong, Vu, Khanh, and Richer, Lawrence

Abstract

Additional file 5. Median healthcare costs during the pre- and post-index periods among the overall and CTO cohorts.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results